

**Table 3 Vascular endothelial function parameters and patient characteristics**

	FMD					RHI				
	Yes		No		p-value	Yes		No		p-value
	n	mean ± SD	n	mean ± SD		n	median (IQR)	n	median (IQR)	
Male gender	64	4.38±2.27	24	5.10±2.49	0.198	64	1.68 (1.47-2.01)	24	2.04 (1.44-2.30)	0.275
NYHA II/III	35	4.50±2.21	53	4.63±2.44	0.810	35	1.67 (1.44-2.15)	53	1.76 (1.54-2.07)	0.520
Hypertension	39	4.33±2.38	49	4.78±2.32	0.376	39	1.68 (1.43-2.17)	49	1.78 (1.53-2.13)	0.798
Diabetes	34	4.29±2.29	54	4.76±2.38	0.366	34	1.71 (1.49-2.06)	54	1.75 (1.43-2.16)	0.925
Dyslipidemia	36	4.24±2.32	52	4.81±2.35	0.266	36	1.71 (1.44-2.07)	52	1.74 (1.52-2.13)	0.993
Chronic kidney disease	47	4.41±2.01	41	4.77±2.68	0.472	47	1.67 (1.42-2.02)	41	1.87 (1.59-2.24)	0.046
Smoking	56	4.71±2.58	32	4.35±1.86	0.494	56	1.68 (1.44-2.04)	32	1.82 (1.51-2.18)	0.665
ACE inhibitors/ARBs	58	4.28±1.92	30	5.16±2.94	0.093	58	1.75 (1.54-2.12)	30	1.63 (1.43-2.13)	0.344
Beta blockers	41	4.78±2.02	47	4.40±2.60	0.461	41	1.78 (1.42-2.23)	47	1.68 (1.53-2.04)	0.808
Loop diuretics	57	5.00±2.26	31	3.80±2.31	0.021	57	1.68 (1.43-2.13)	31	1.84 (1.57-2.17)	0.305
Statins	61	4.52±2.25	27	4.70±2.58	0.738	61	1.67 (1.43-2.97)	27	1.84 (1.60-2.18)	0.220
Anti-diabetic drugs	30	4.45±2.23	58	4.64±2.41	0.716	30	1.65 (1.43-1.92)	58	1.78 (1.53-2.16)	0.353

FMD and RHI was compared between two groups of present (yes) and absent (no) in each item for baseline characteristics represented as categorical variables.

FMD, flow-mediated dilation; RHI, reactive hyperemia index; SD, standard deviation; IQR, interquartile range; NYHA, New York Heart Association; ACE, angiotensin converting enzyme; ARBs, angiotensin receptor blockers